The Frazier Life Sciences team invests in and builds companies developing and commercializing novel therapeutics.

500+

Collective years of investing and operational experience

100

Portfolio companies

60

M&A and IPOs

29

FDA approved drugs since 2010

Selected M&A and IPOs

Acquired by AstraZeneca in 2016
IPO in 2014; Acquired by Roche in 2018
NASDAQ: IOVA
Acquired by AbbVie in 2019
IPO in 2019 (NASDAQ: MIRM)
IPO in 2019 (NASDAQ: PHAT)
Acquired by CutisPharma in 2019
Acquired by Allergan in 2016

Life Sciences News

Frazier Life Sciences Team

Frazier Healthcare Partners Closes Oversubscribed $617 Million Life Sciences Fund

Frazier Life Sciences Team

Frazier Healthcare Partners Announces Multiple Promotions on its Life Sciences Team

Mavupharma

AbbVie Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma

Silvergate Pharmaceuticals

CutisPharma Announces Acquisition of Silvergate Pharmaceuticals, Name Change to Azurity Pharmaceuticals

View All News